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Expression by the liver of a viral protein induced an
immunologic tolerance mediated by interleukin-10-
secreting regulatory T cells that impaired the antiviral
T-cell response, leading to a chronic infection. This mecha-
nism could be involved in the establishment of persistent
infection by hepatotropic viruses.
BACKGROUND & AIMS: The constant exposure of the liver to
food and bacterial antigens through the mesenteric circulation
requires it to maintain tolerance while preserving the ability to
mount an effective immune response against pathogens. We
investigated the contribution of the liver’s tolerogenic nature
on the establishment of chronic viral infections.
METHODS: TTR-NP mice, which express the nucleoprotein
(NP) of lymphocytic choriomeningitis virus (LCMV) speciﬁcally
in hepatocytes under control of a modiﬁed transthyretin (TTR)
promoter, were infected with the Armstrong (Arm) or WE acute
strains of LCMV.
RESULTS: The infection persisted for at least 147 days in
TTR-NP mice. Expression of NP by the liver induced a strong
peripheral tolerance against NP that was mediated by inter-
leukin-10-secreting CD4þ regulatory T cells, leading to high
PD-1 (programmed death-1) expression and reduced effector
function of virus-speciﬁc T cells. Despite an active immune
response against LCMV, peripheral tolerance against a single
viral protein was sufﬁcient to induce T-cell exhaustion and
chronic LCMV Armstrong (Arm) or WE infection by limiting the
antiviral T-cell response in an otherwise immunocompetent
host. Regulatory T-cell depletion of chronically infected TTR-NP
mice led to functional restoration of LCMV-speciﬁc CD4þ and
CD8þ T cell responses and viral clearance.
CONCLUSIONS: Expression of a viral antigen by hepatocytes can
induce a state of peripheral tolerance mediated by regulatory
T cells that can lead to the establishment of a chronic viral
infection. Strategies targeting regulatory T cells in patients
chronically infected with hepatotropic viruses could represent a
promising approach to restore functional antiviral immunity and
clear infection. (Cell Mol Gastroenterol Hepatol 2015;1:325–341;
http://dx.doi.org/10.1016/j.jcmgh.2015.02.002)Institute. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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http://dx.doi.org/10.1016/j.jcmgh.2015.02.002Keywords: Chronic Infection; Hepatitis; Tolerance.he liver is an immunoprivileged site prone toTtolerance induction. For example, liver grafts are
accepted without immunosuppression in several mammals,1
and oral tolerance is abrogated when a portacaval shunt is
performed.2 The liver also has the unique ability among
solid organs to activate naive CD8þ T lymphocytes in an
antigen-speciﬁc manner, a process that can be inefﬁcient
and lead to apoptosis through a Bim-dependant pathway.3
The liver is also host to several chronic infections, but
infection of the liver does not inevitably lead to viral
persistence. Strong innate immune responses combined
with speciﬁc T-cell responses can overcome viral escape
mechanisms—as in hepatitis A infection or resolved acute
hepatitis B (HBV) or C virus (HCV) infections—and achieve
viral clearance. However, as observed in 50% to 80% of
HCV infections, pathogens can evade early innate and
adaptive immune responses through high antigen loads and
increased coinhibitory signaling locally in the inﬂamed liver,
leading to T-cell exhaustion and viral persistence.4
After exposure, HCV reaches maximal titers several
weeks before the induction of detectable humoral or cellular
immune responses and the onset of liver disease; in cases
where HCV titers remain relatively low, T cell responses
may remain undetectable even during chronic infection.5
Therefore, the liver may be exposed to HCV antigens in
absence of strong immune responses. It has recently been
shown in a model of chronic viral infection that CD4þ reg-
ulatory T-cell depletion in combination with programmed-
death-ligand-1 (PD-L1) blockade can signiﬁcantly reduce
viral titers, highlighting the importance of immune inhibi-
tory signals in the outcome of viral infections.6 Thus, the
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gens could contribute to the development of chronic liver
infections by altering the immunologic response against
liver-expressed viral antigens.7 Therefore, we directly
assessed whether expression of a viral antigen by hepato-
cytes can induce a state of peripheral tolerance able to
contribute to viral persistence.
We show that expression of the nucleoprotein (NP) from
lymphocytic choriomeningitis virus (LCMV) speciﬁcally in
hepatocytes leads to strong peripheral tolerance mediated
by interleukin-10 (IL-10)-secreting CD4þ forkhead box P3þ
(FoxP3þ) regulatory T cells. This allows the establishment
of chronic infection by acute strains of LCMV associated
with the loss of CD4þ and CD8þ T-cell effector function,
leading to high viral titers in the liver and spleen. Depletion/
silencing of CD4þ regulatory T cells resulted in the pro-
gressive restoration of T-cell function, loss of PD-1 (pro-
grammed death-1) expression, and gradual viral clearance.
This study demonstrates that expression of a viral antigen in
the liver leads to the development of CD4þ regulatory
T cells able to interfere with the antiviral T-cell response,
allowing the establishment of a chronic infection.
Materials and Methods
Mice and Viruses
Transthyretin-nucleoprotein (TTR-NP) transgenic mice8
(8- to 12-week-old females) expressing LCMV NP specif-
ically in hepatocytes (kindly provided by F. Alvarez, CHU
Sainte-Justine, Montreal, Canada) or control C57BL/6 (B6)
mice (8- to 12-week-old females) (Charles River, Montreal,
Canada) were infected with either acute strains LCMV-Arm
(200 plaque-forming units [pfu] intraperitoneally [IP]) or
LCMV-WE (200 pfu intravenously [IV]). Hemizygous TTR-
NP1/0 mice were generated as a F1 cross between homo-
zygous TTR-NP and C57BL/6 mice. The NP396–404-speciﬁc
T-cell receptor (TCR) transgenic TNP4 mice9 were kindly
provided by F. Alvarez (CHU Sainte-Justine). The glycopro-
tein GP33–41-speciﬁc TCR transgenic P14 mice were kindly
provided by P. Ohashi (Princess Margaret Cancer Centre,
Toronto, Canada). The recombination-activating gen-
e–nucleoprotein (RAG-NP) mice were obtained by crossing
TTR-NP and RAG-1 mice (kindly provided by C Daniel, INRS-
Institut Armand-Frappier, Laval, Quebec, Canada). The RAG-1
phenotype was assessed by ﬂow cytometry, and NP expres-
sion was monitored by polymerase chain reaction, as previ-
ously described elsewhere.8
LCMV-WE and Armstrong strains were obtained from
R.M. Zinkernagel at the Institute of Experimental Immu-
nology (Zurich, Switzerland). LCMV titration was performed
via a standard focus-forming assay. All experiments were
performed under protocols approved by the INRS Institu-
tional Committee for Animal Care and following guidelines
published by the Canadian Council on Animal Care.
Lymphocyte Isolation From Liver and Spleen
Livers were perfused via the portal vein with RPMI 1640
(Thermo Fisher Scientiﬁc, Mississauga, ON, Canada) and
removed. The livers and spleens were ﬁnely minced in RPMI1640, passed through a 100-gauge steel mesh, and centri-
fuged at 400g for 5 minutes at 4C. Cells contained in the
supernatant were washed 3 times with RPMI 1640/5% fetal
calf serum before being centrifuged on a Percoll (GE
Healthcare Canada, Mississauga, ON, Canada) gradient to
purify lymphocytes.10
Flow Cytometry
For the ﬂow cytometry analysis, isolated cells were
washed, resuspended in phosphate-buffered saline con-
taining 5% fetal calf serum (ﬂuorescence-activated cell
sorter [FACS] buffer), and incubated with directly conju-
gated primary antibodies for 30 minutes at 4C. Cells were
then washed and resuspended in 200 mL FACS buffer con-
taining 1% formaldehyde. Class I tetramer staining was
performed using phycoerythrin (PE)-coupled NP396–404 and
GP33–41 H2-D
b-restricted tetramers for 30 minutes at 37C
in FACS buffer followed by surface staining. Anti-CD25
allophycocyanin (APC) was purchased from eBioscience
(San Diego, CA). Anti-CD45 PE/CF594 was purchased from
BD Biosciences (San Jose, CA). Anti-PD-1 ﬂuorescein iso-
thiocyanate and anti-PD-1 allophycocyanin (APC), anti-CD4
APC/Cy7, anti-CD4 ﬂuorescein isothiocyanate, anti-CD8
PE/Cy7, anti-CD62L Alexa Fluor 700, anti-CD44 PercP/
Cy5.5, anti-CD3 APC, interferon-g (IFN-g) PE, tumor ne-
crosis factor-a (TNF-a) APC, and B and T lymphocyte
attenuator (BTLA) Alexa Fluor 647 were purchased from
BioLegend (San Diego, CA). Intracellular FoxP3 staining was
performed using PE-coupled anti-mouse/rat FoxP3 anti-
body (clone FJK-16s) and ﬁxation/permeabilization buffer
optimized for staining of mouse cells with FJK-16s mono-
clonal antibodies (eBioscience). Intracellular staining of
Helios was performed using Alexa Fluor 647 coupled anti-
mouse Helios antibody (clone 22F6) (eBioscience) and us-
ing the ﬁxation/permeabilization buffer optimized for
staining of mouse cells with FoxP3 (FJK-16s) monoclonal
antibodies (eBioscience). Ki-67 protein intracellular staining
was performed using anti-mouse/rat Ki-67 eﬂuor450 con-
jugated antibody (clone SolA15) (eBioscience). Class II
tetramer staining (NIH Tetramer Core Facility, Atlanta, GA)
(PE-labeled H2-IAb GP31–45, GP66–77, NP309–328, or control
H2-IAb hCLIP) was performed at 37C for 3 hours (2 mg/
mL) in FACS buffer. The cells were then washed in FACS
buffer, surface stained (CD3, CD4, CD8, CD44, CD62L, CD25,
and 7-AAD viability stain) (eBioscience and BioLegend), and
ﬁxed. Samples were acquired on a BD LSRFortessa (BD
Biosciences) and analyzed using the FlowJo software (Tree
Star, Ashland, OR).
Intracellular Cytokine Staining
Intracellular cytokine staining was performed using
isolated lymphocytes stimulated for 5 hours in the presence
of 10 U/mL IL-2 and Brefeldin A (10 mg/mL) and one of
GP33–41, NP396–404, GP61–80 peptide, or NP311–325 (5 mg/mL).
Cells were stained for surface and viability markers as
described earlier, and then they were ﬁxed and per-
meabilized for intracellular staining using ﬁxation and per-
meabilization buffers from BioLegend. Cells were then
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were acquired on a BD LSRFortessa (BD Biosciences) and
analyzed using the FlowJo software (Tree Star).
Type I Interferon and Interleukin-10 Measurement
The IFN-a levels were measured in sera, liver, and spleen
homogenates in LCMV-infected B6 and TTR-NP mice with
the Verikine mouse IFN-a enzyme-linked immunoassay
(ELISA) kit (PBL Interferon Source, Piscataway, NJ) accord-
ing to the manufacturer’s instructions. IFN-b levels were
measured in sera of infected B6 and TTR-NP mice with the
Verikine mouse IFN ELISA kit (PBL Interferon Source). The
IL-10 serum levels were measured using the multiplex bead
immunoassay (Life Technologies/Gibco, Grand Island, NY).
In Vivo Cytotoxicity Assay
The cytotoxicity assay was performed using carboxy-
ﬂuorescein diacetate succinimidyl ester (CFSE)-labeled
target cells from naive B6 mice (0.2 mM, 1 mM or 5 mM)
coated with either the GP33–41 or NP396–404 peptide (1 mM)
or left uncoated (negative control), respectively. These cells
(1  107 cells each) were injected IV simultaneously in
infected or control mice. The mice were killed 4 hours later,
and lymphocytes from the spleen and lymph nodes were
isolated. Cells were analyzed by ﬂow cytometry on a BD
LSRFortessa (BD Biosciences) using the FlowJo software
(Tree Star).
In Vitro Proliferation Assay
Puriﬁed CD8þ T cells (Stemcell Technologies, Vancouver,
BC, Canada) from the spleen and liver were labeled with
CFSE (5 mM) (Vybrant CFDA SE Cell Tracer Kit; Molecular
Probes, Eugene, OR) and were incubated with syngeneic
puriﬁed antigen-presenting cells from the spleen,11 previ-
ously coated with 1 mM of GP33–41 or NP396–404 peptide,
supplemented with 5% fetal calf serum and 30 U/mL of
murine recombinant IL-2 (Invitrogen, Carlsbad, CA). After 3
days, cells were labeled with an anti-CD8 antibody (eBio-
science) and 7-AAD (Invitrogen). The cells were analyzed by
ﬂow cytometry on a BD LSRFortessa (BD Biosciences) and
using the FlowJo software (Tree Star).
In Vivo Proliferation Assay
CD8þ T cells were puriﬁed from P14 (GP33–41-speciﬁc
TCR) and TNP4 (NP396–404-speciﬁc TCR) transgenic mice
using the EasySep mouse CD8þ T-cell enrichment kit
(Stemcell Technologies). Puriﬁed CD8þ T cells (1.5  106)
from P14 mice were stained with CFSE (5 mM) (Vybrant
CFDA SE Cell Tracer Kit; Molecular Probes), and cells from
TNP4 mice (1.5  106) with Cell Proliferation Dye e450 (10
mM) (eBioscience). We adoptively transferred 1.5  106
CD8þ T cells from P14 and TNP4 mice by IV route into TTR-
NP and B6 control mice. The next day, the mice were
infected with 200 pfu of LCMV-Arm IP, and they were killed
4 days later.
Alternatively, 1.5  106 CD8þ T cells from P14 and TNP4
mice (Stemcell Technologies) were adoptively transferredIV into RAG-NP and RAG control mice. The mice were killed
7 days later. Isolated lymphocytes from the spleen and liver
were stained (CD3, CD4, CD8, and 7-AAD), and the prolif-
eration of CFSE and e450-labeled cells was analyzed by ﬂow
cytometry on a BD LSRFortessa (BD Biosciences) and using
the FlowJo software (Tree Star).
Adoptive T Cell Transfer Into RAG-NP Mice
Splenocytes from B6 mice (1  108 cells) were trans-
ferred IV into RAG-NP or RAG control mice. After 14 days,
mice were killed, and the T cells were surface stained with
CD4, CD8, CD25, CD62L, and CD44 (BioLegend) and intra-
cellularly for FoxP3 and Ki-67 (eBioscience).
Adoptive T Cell Transfer Into TTR-NP
We labeled 2  106 puriﬁed CD8þ T cells from P14
(GP33–41) or TNP4 mice (NP396–404) (Stemcell Technologies)
with CFSE (5 mM) (Vybrant CFDA SE Cell Tracer Kit; Mo-
lecular Probes), and they were adoptively transferred IV
into TTR-NP or control B6 mice. Two days after transfer, the
T cells were isolated from the spleen and liver, and they
were analyzed by ﬂow cytometry for proliferation, expres-
sion of activation markers (CD25 APC, CD62L Alexa Fluor
700, or CD69 PE) (BioLegend and eBioscience), or intra-
cellular expression of Bim Alexa Fluor 647 (AbD Serotech,
Raleigh, NC).
In Vivo Regulatory CD4þCD25þ T-Cell
Depletion/Silencing
LCMV-infected TTR-NP mice (45 days after infection)
were injected IP with 200 mg of anti-CD25 antibodies
(PC61.5 clone) or 200 mg of IgG1 isotypic control (BioXcell,
West Lebanon, NH) every 7 days. The CD4þCD25þ regula-
tory T cell depletion was conﬁrmed by ﬂow cytometry. The
mice were killed 28 days after the start of regulatory T cell
(Treg) depletion.
Quantiﬁcation of LCMV NP Expression
Levels by Flow Cytometry
To measure the expression levels of LCMV NP on liver
cells, puriﬁed anti-NP antibodies from the monoclonal IgG-
secreting hybridoma VL4 (kindly given by R.M. Zinkerna-
gel, Institute of Experimental Immunology, Switzerland)
were coupled to Alexa Fluor 647 using the Alexa Fluor
Protein Labeling Kit (Life Technologies, Rockville, MD).
Mechanically disrupted liver cells were separated on a
discontinuous 40%/80% Percoll (GE Healthcare Canada)
gradient to separate parenchymal from nonparenchymal
cells. Parenchymal cells were stained with ﬂuorochrome
labeled anti-CD45, 7-AAD, and Alexa647-anti-NP and were
analyzed by ﬂow cytometry on a BD LSRFortessa (BD Bio-
sciences) and using FlowJo (Tree Star).
Serum Alanine Aminotransferase Levels
Serum aminotransferase (ALT) levels were measured
using a TRILOGY Multipurpose Analyzer system (DREW
Scientiﬁc, Dallas, TX).
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Differences between groups were tested using one-way
analysis of variance (ANOVA) with Tukey’s post hoc test.
The Student t test was used when two groups were
compared. In all graphs, the error bars represent the stan-
dard error of the mean. All statistical analyses were per-
formed using GraphPad Prism version 5 (GraphPad
Software, La Jolla, CA).Results
Expression of LCMV Nucleoprotein by
Hepatocytes in TTR-NP Mice Leads to Chronic
Infection With Acute Strains of LCMV
TTR-NP mice express LCMV NP speciﬁcally in hepato-
cytes under the control of a modiﬁed transthyretin (TTR)
promoter.8 This liver-speciﬁc transthyretin minimal
enhancer promoter sequence limits expression to hepato-
cytes without any detectable expression in the spleen,
thymus, muscle, or kidney.8 TTR-NP mice were infected
with low doses (200 pfu) of LCMV-Arm or WE. Infected mice
showed a gradual increase in serum alanine aminotrans-
ferase (ALT) levels 55 days after infection indicative of
chronic hepatitis (Figure 1A). Infected TTR-NP mice showed
20% to 30% mortality rates compared with 0% for infectedFigure 1. Transthyretin-nucleoprotein (TTR-NP) mice are ch
riomeningitis virus (LCMV). (A) Alanine aminotransferase (ALT)
WE and LCMV-Armstrong (200 plaque-forming units [pfu]). Norm
TTR-NP and B6 mice. (C) LCMV-WE titers in TTR-NP and B6
percentage of recovered virus per organ 147 days after LCMV
dependent experiments are shown; n ¼ 4–12 per group.)B6 mice (see Figure 1B). The LCMV titers in infected TTR-
NP mice were higher on day 8 than in B6 mice and
remained high in the spleen, liver, and kidney for over 147
days after infection (see Figure 1C). Within each infected
mouse, the majority of virus was found in liver (see
Figure 1C).Active Antiviral Immune Response in Infected
TTR-NP Mice With High PD-1 Levels on
LCMV-Speciﬁc CD8þ and CD4þ T Cells
Fifty-ﬁve days after LCMV infection, TTR-NP mice
showed higher proportions of effector CD8þ T cells in the
spleen and among liver-inﬁltrating lymphocytes (LIL)
compared with infected B6 mice (Figure 2A). Beginning on
day 8 and increasing until day 55 after infection, TTR-NP
mice showed high PD-1 expression on CD8þ and CD4þ T
cells (see Figure 2B). The PD-1 expression was higher on
effector/memory CD8þ T cells than on naive CD8þ T cells in
infected TTR-NP mice (see Figure 2C). The levels of PD-1 on
epitope-speciﬁc CD8þ and CD4þ T cells were measured
using class I and II tetramers (gating strategy described in
Supplementary Figure 1). The PD-1 levels were elevated on
NP396–404 and GP33–41 CD8
þ T cells from TTR-NP mice
compared with the B6 mice (see Figure 2D). The levels ofronically infected with acute strains of lymphocytic cho-
levels in TTR-NP and B6 mice infected with low-dose LCMV-
al levels are shown (dotted line). (B) Survival of LCMV-infected
mice8 at 8, 55, and 147 days after infection. Shown is the
-WE infection (right panel). (Representative data of three in-
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Figure 3. Lymphocytic
choriomeningitis virus
(LCMV)-speciﬁc CD4D
and CD8D T-cell re-
sponses in infected
transthyretin-nucleopro-
tein (TTR-NP) mice. (A)
Class I tetramer staining
(NP396–404 and GP33–41) of
CD8þ T cells from spleen
and liver of TTR-NP and B6
mice at 8 and 55 days after
infection with low-dose
(200 plaque-forming units
[pfu]) LCMV-WE. (B) Class II
tetramer staining (IAb
NP309–328,GP66–77,GP31–45)
of CD4þ T cells from the
spleen and liver of TTR-NP
and B6 mice at 8 and 55
days after infection. Pro-
portions of class I and II
tetramer-positive CD8þ or
CD4þ T cells among total
CD8þ or CD4þ T cells are
shown. (Representative
data of two to three inde-
pendent experiments are
shown; n ¼ 4 per group.)
*P < .05, **P < .01,
***P < .001.
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þ T cells from TTR-NP mice
were also signiﬁcantly higher than those of GP33–41 CD8
þ
T cells from TTR-NP mice (see Figure 2D). The levels of PD-
1 on GP31–45, GP66–77, and NP309–328 CD4
þ T cells from TTR-
NP mice were signiﬁcantly higher than on those from the
infected B6 mice (see Figure 2E).Normal Type I Interferon Response in
LCMV-Infected TTR-NP Mice
Type I IFN is critical for the development of a proper
T-cell response against LCMV.12 In vitro, LCMV NP has beenFigure 2. (See previous page). Lymphocytic choriomeningitis v
transthyretin-nucleoprotein (TTR-NP) mice express high pro
naive, CD62LþCD44þ central memory (TCM), and CD62LCD
infection. (B) Expression of PD-1 by CD8þ and CD4þ T cells from
dose lymphocytic choriomeningitis virus (LCMV)-WE infection.
cells from TTR-NP and B6 mice at 55 days after infection. Exp
togram of PD-1 expression on CD44þCD62L effector/memory
cells (grey). (D) Mean ﬂuorescence intensity (MFI) of PD-1 expre
and B6 mice 55 days after infection. (E) MFI of PD-1 expression
mice 55 days after infection. (F) Type 1 interferon levels in serum
data of two to three independent experiments are shown; n ¼shown to inhibit the type I IFN response.13 The IFN-a and -b
levels in the serum, spleen, and liver of infected TTR-NP and
B6 mice were compared, and no signiﬁcant differences were
observed (see Figure 2F).TTR-NP Mice Are Tolerant to LCMV NP
The TTR-NP mice showed no sign of massive NP-speciﬁc
clonal deletion, as the CD8þ and CD4þ T-cell responses
against NP were readily detectable by class I and II tetramer
staining (Figure 3). Nonetheless, proportions of NP396–404-
speciﬁc CD8þ T cells were reduced in both the spleen andirus (LCMV)-speciﬁcCD8D and CD4D T cells from infected
grammed death-1 (PD-1) levels. (A) Levels of CD62LþCD44
44þ effector memory CD8þ T cells (TEM) at 55 days after
TTR-NP mice (dark line) and B6 mice (grey shading) after low-
(C) PD-1 expression on naive and activated/memory CD8þ T
ression of PD-1 versus CD44 on CD8þ T cells (left) and his-
CD8þ T cells (black line) and on CD44CD62Lþ naive CD8þ T
ssion on LCMV-speciﬁc CD8þ T cells from infected TTR-NP
on LCMV-speciﬁc CD4þ T cells from infected TTR-NP and B6
, spleen, and liver of LCMV-WE-infected mice. (Representative
4 per group.) *P < .05, **P < .01, ***P < .001.
Figure 4. Hepatocyte-
activated nucleoprotein-
speciﬁc CD8D T cells in
uninfected transthyretin-
nucleoprotein (TTR-NP)
mice do not express pro-
apoptotic Bim protein. (A)
2  106 carboxyﬂuorescein
diacetate succinimidyl
ester (CFSE)-labeled naive
CD8þ NP396–404-speciﬁc T
cells isolated from TNP4
mice were transferred IV
into uninfected TTR-NP
and B6 mice. Two days af-
ter the adoptive transfer,
the proliferation of CFSE-
labeled cells was as-
sessed. (B) Expression of
activation markers CD62L,
CD25, and CD69 was
assessed on NP396–404-
speciﬁc T cells 2 days after
adoptive transfer in TTR-
NP or B6 mice. (C) Isolated
CFSE-labeled NP396–404
and GP33–41-speciﬁc CD8
þ
T cells from TNP4 and P14
transgenic mice, respec-
tively, were adoptively
transferred into TTR-NP
and B6 mice and analyzed
for Bim expression by ﬂow
cytometry 2 days after
transfer. (Representative
data of two independent
experiments are shown;
n ¼ 4 per group.)
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days after infection (Figure 3A). Eight days after infection,
proportions of NP309–328-speciﬁc CD4
þ T cells were also
reduced in both the spleen and liver of TTR-NP mice
compared with B6 mice. Fifty-ﬁve days after infection, the
levels of NP309–328-speciﬁc CD4
þ T cells were reduced in the
spleen but similar in the liver (see Figure 3B). The levels of
GP-speciﬁc CD8þ (GP33–41) and CD4
þ T cells (GP31–45 and
GP66–77) were similar or higher in TTR-NP mice 8 and 55
days after LCMV infection compared with B6 mice. Primary
activation by hepatocytes or liver-resident antigen-pre-
senting cells of naive CD8þ T cells can result in a “neglected”
phenotype characterized by poor cytotoxic-T lymphocyte
(CTL) function, high Bim expression, and cell death.3Adoptive transfer of CFSE-labeled naive NP396–404-speciﬁc
T cells isolated from TNP4 TCR transgenic mice9 in unin-
fected TTR-NP mice led to limited T-cell proliferation, CD69
up-regulation, and a lack of CD25 expression (Figure 4).
However, Bim expression levels were not increased (see
Figure 4).
These observations are consistent with the fact that
although NP396–404-speciﬁc T cells are present in fewer
numbers in LCMV-infected TTR-NP mice, they are not
deleted (see Figure 3). Cytokine-producing LCMV-speciﬁc
CD8þ T cells were reduced in the spleen of TTR-NP mice
compared with B6 mice 55 days after infection. Fewer
polyfunctional TNF-aþ IFN-gþ CD8þ T cells were detected
after stimulation with GP33–41 and very few after
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CD4þ T-cell responses were similarly reduced in TTR-NP
mice compared with B6 mice, with very few cells respond-
ing to NP311–325 peptide stimulation (see Figure 5A, upper
right panel). Therefore, although TTR-NP mice mount CD4þ
and CD8þ T-cell responses against both NP and GP-derived
epitopes after the establishment of chronic LCMV infection
(see Figure 3), these cells secrete fewer cytokines 8 days
after LCMV infection (see Figure 5A, lower left panel), and
their levels remained low throughout chronic infection (see
Figure 5A, lower right panel), especially those targeting NP-
derived epitopes.
This reduced number of NP-speciﬁc polyfunctional
(TNF-aþ IFN-gþ) T cells could limit the ability of TTR-NP
mice to eliminate infected cells and control viral burden.
To test this, an in vivo cytotoxicity assay was performed in
B6 and TTR-NP mice 30 days after infection. The LCMV-
infected B6 mice developed strong CTL responses against
both GP33–41 and NP396–404 pulsed cells (see Figure 5B),
resulting in their rapid elimination. In TTR-NP mice an
efﬁcient CTL response against GP33–41-labeled target cells
was detected whereas the response against NP396–404-
pulsed target cells was undetectable (see Figure 5B). The
in vitro proliferative capacity of these cells was also
compromised, as NP396–404-speciﬁc T cells in TTR-NP mice
did not proliferate in response to peptide stimulation
whereas GP33–41-speciﬁc T cells did (see Figure 5C).
BTLA is expressed on T cells after antigen-speciﬁc in-
duction of anergy in vivo.14 BTLA levels were statistically
signiﬁcantly higher on NP396–404
þ CD8þ T cells from infec-
ted TTR-NP mice than on GP33–41
þ T cells or on those from
control B6 mice (see Figure 5D).Efﬁcient Presentation of Hepatocyte-Expressed
NP to CD8þ T Cells
To assess the efﬁciency of NP presentation early during
LCMV infection in TTR-NP mice, GP33–41 and NP396–404-
speciﬁc CD8þ T cells isolated respectively from P14 and
TNP4 TCR transgenic mice were labeled with CFSE or
eﬂuor450, respectively, and were adoptively transferred
into TTR-NP and B6 mice before LCMV infection. Prolifera-
tion of GP33–41- and NP396–404-speciﬁc T cells in the spleen
was analyzed 5 days later. The GP33–41-speciﬁc CD8
þ T cells
proliferated more than the NP396–404-speciﬁc T cells in B6
mice, highlighting the previously reported immunodomi-
nance of this epitope at this early stage of LCMV infection15
(Figure 6A). However, although the GP33–41-speciﬁc prolif-
eration was similar between TTR-NP and B6 mice,
NP396–404-speciﬁc proliferation was increased in TTR-NPFigure 5. (See previous page). Transthyretin-nucleoprotein (T
virus (LCMV)-NP-derived T-cell epitopes. (A) Proportions of C
and 55 days after LCMV-WE infection secreting both tumor nec
NP396–404, GP33–41, or control peptide stimulation in vitro. (B) In
LCMV-WE infection. (C) CFSE proliferation assay of CD8þ T cel
B6 mice in response to GP33–41 or NP396–404 T-cell epitopes. (D)
tetramer positive NP396–404- and GP33–41-speciﬁc T cells from
(Representative data of three independent experiments are shomice, suggesting that NP396–404-T cells are not anergic at
early stages of infection (see Figure 6A). However, the
impact of endogenous versus viral LCMV-NP expression on
NP396–404-T cell proliferation was indistinguishable in this
setting.
To test the hypothesis that endogenous NP in absence of
LCMV-expressed NP could lead to the observed NP396–404-
speciﬁc T-cell proliferation, GP33–41- and NP396–404-speciﬁc
T cells were adoptively transferred into uninfected RAG-
deﬁcient and RAG-deﬁcient TTR-NP mice (RAG-NP). Naive
T cells expand in RAG-deﬁcient mice, mostly through an IL-7
driven homeostatic T-cell proliferation process,16 thereby
facilitating the determination of the proliferation of NP-
speciﬁc T cells in presence of survival factors (IL-7)
without the interference of LCMV-expressed NP. RAG-
deﬁcient animals also lack any prior Treg-mediated toler-
ance to NP that could interfere with NP presentation. Seven
days after adoptive transfer, NP396–404-speciﬁc T-cell pro-
liferation was increased in RAG-NP mice compared with
RAG mice whereas GP33–41-speciﬁc T-cell proliferation was
similar (see Figure 6B). Therefore, endogenous NP can lead
to the proliferation of NP396–404-speciﬁc T cells in RAG-NP
mice.
Taken together these results indicate that although TTR-
NP mice are hyporesponsive toward NP after LCMV infec-
tion, this does not result from liver-mediated NP396–404
CD8þ T-cell deletion (see Figure 4) or ineffective T-cell
activation through tolerizing endogenous NP presentation
(see Figure 6A and B).
CD4þ FoxP3þ Regulatory T Cell Conversion/
Expansion in TTR-NP Mice
To determine whether Tregs could speciﬁcally convert/
expand in response to liver-expressed NP, 1  108 spleno-
cytes from B6 mice were adoptively transferred into RAG
and RAG-NP mice, and the T-cell proliferation was moni-
tored by Ki-67 staining. This number of adoptively trans-
ferred cells in a RAG-deﬁcient mouse, while minimizing
homeostatic proliferation, facilitated tracking of prolifera-
tion based solely on NP expression and was not inﬂuenced
by preestablished tolerance to NP. The CD4þ FoxP3þ cells,
but not the CD4þ FoxP3 T cells, showed an increased Ki-67
expression in RAG-NP mice in comparison with RAG mice
(Figure 7A).
CD4þ Regulatory T Cell Expansion in Infected
TTR-NP Mice
The number of CD4þ FoxP3þ regulatory T cells before
LCMV infection was not statistically signiﬁcantly differentTR-NP) mice are tolerant to lymphocytic choriomeningitis
D8þ T cells isolated from infected TTR-NP and B6 mice at 8
rosis factor-a (TNF-a) and interferon-g (IFN-g) in response to
vivo cytotoxicity assay in TTR-NP and B6 mice 30 days after
ls isolated from the spleen of LCMV-WE infected TTR-NP and
Expression levels of B and T lymphocyte attenuator (BTLA) on
TTR-NP and B6 mice at 55 days after LCMV-WE infection.
wn; n ¼ 4 per group.) *P < .05, **P < .01.
Figure 6. Hepatocyte-
expressed NP is efﬁ-
ciently presented and
leads to CD8D T-cell
activation. (A) GP33–41-
and NP396–404-speciﬁc
CD8þ T cells isolated from
P14 and TNP4 TCR trans-
genic mice and labeled
with CFSE or eﬂuor450,
respectively, were adop-
tively transferred (1.5  106
cells) into transthyretin-
nucleoprotein (TTR-NP)
and B6 mice before low-
dose infection with lym-
phocytic choriomeningitis
virus (LCMV)-WE. Prolifer-
ation was assessed by
ﬂow cytometry 5 days after
infection. (B) GP33–41- and
NP396–404-speciﬁc CD8
þ T
cells were labeled as
described and were adop-
tively transferred into
recombination-activating
gene (RAG)-deﬁcient or
RAG-deﬁcient TTR-NP
mice to monitor the prolif-
eration in absence of
infection. Proliferation was
assessed 7 days later by
ﬂow cytometry. The GP33–41
(CFSE) and NP396–404
speciﬁc (eﬂuor450) CD8þ
T cells before transfer
(dashed lines) are shown
as controls. (Representa-
tive data of two indepen-
dent experiments are
shown; n ¼ 4 per group.)
**P < .01.
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(see Figure 7B). Eight days after LCMV-WE infection, the
number of splenic Tregs in B6 mice decreased slightly while
their numbers remained elevated in infected TTR-NP mice
(see Figure 7B). The number of liver Tregs was low and did
not signiﬁcantly vary after infection (Figure 7B).
Similar results were obtained after LCMV-Arm infection.
The TTR-NP mice showed a signiﬁcant increase in the
proportion of CD4þ FoxP3þ T cells among the CD4þ T cells
after infection with LCMV-WE or LCMV-Arm compared with
the B6 mice in both the spleen and liver (see Figure 7C),
and they remained elevated throughout the chronic infec-
tion. The FoxP3þ regulatory T cells from infected TTR-NP
mice expressed statistically signiﬁcantly higher levels ofHelios than those from infected B6 mice (see Figure 7D).
Fifty-ﬁve days after infection, the serum levels of IL-10
were statistically signiﬁcantly higher in the infected TTR-
NP mice than in the B6 mice and remained elevated up to
147 days after infection (see Figure 7E). In these mice,
CD4þFoxP3þ regulatory T cells were responsible for the
majority of IL-10 production among splenocytes (see
Figure 7F).Level of NP Expression in Hepatocytes Is Critical
for the Establishment of LCMV Chronicity
The expression levels of NP in the liver of TTR-NP mice
could have a direct impact on the fate of CD8þ T cells17 and
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TTR-NP1/0 mice expressing NP at half the levels of that of
TTR-NP mice were used (Figure 8A). The number of CD4þ
regulatory T cells before infection was similar between TTR-
NP1/0 and TTR-NP mice in both the spleen and liver (see-
Figure 8B). However, the signiﬁcant expansion of CD4þ
FoxP3þ Tregs observed in the TTR-NP mice after LCMV
infection was not seen in the hemizygous TTR-NP1/0 mice
(see Figure 8C). LCMV infection of hemizygous TTR-NP1/0
mice led to increased IFN-g and TNF-a CD8þ T cell re-
sponses against both GP33–41 and NP396–404 epitopes
compared with the TTR-NP mice. However, the NP396–404
T cell responses did not reach that of infected B6 mice (see
Figure 8D).
T cells from hemizygous TTR-NP1/0 mice showed
increased in vivo cytotoxicity against NP-expressing
target cells compared with LCMV-infected TTR-NP mice
while remaining lower than that of B6 mice (see
Figure 8E). Despite the impaired T-cell response against
NP-derived epitopes in hemizygous TTR-NP1/0 mice,
infection with acute strains of LCMV did not persist (see
Figure 8F).Depletion/Silencing of CD4þ Regulatory T Cells
Leads to Viral Clearance in Chronically Infected
TTR-NP Mice
To ascertain the role of CD4þ regulatory T cells in viral
persistence of infected TTR-NP mice, these cells were
depleted/silenced using CD25-speciﬁc antibodies. Forty-ﬁve
days after LCMV infection, the TTR-NP mice were
injected weekly with anti-CD25 antibodies (PC61.5) or
isotypic control. Treatment reduced the levels of
CD4þCD25þFoxP3þ T cells by 96.8% ± 2.1% in the spleen
and 87.6% ± 1.6% in the liver. Over a 28-day period, the
PD-1 expression by CD4þ and CD8þ T cells gradually
returned to control levels (Figure 9A). CD8 T-cell function-
ality was also improved, with increased numbers of IFN-gþ
TNF-aþ CD8þ T cells after stimulation with GP33–41 and
NP396–404 peptides (see Figure 9B).
The serum levels of IL-10 were signiﬁcantly reduced in
infected Treg-depleted/silenced TTR-NP mice compared
with infected TTR-NP mice (see Figure 9C). LCMV viremia
gradually declined, and the mice achieved viral clearance 28
days after beginning the anti-CD25 treatment (see
Figure 9D).Figure 7. (See previous page). Interleukin-10 (IL-10)-secreting
choriomeningitis virus (LCMV) infection of transthyretin-nucl
transferred (1  108 T cells from B6 mice) into recombination-a
expression 7 days after transfer. (B) Number of CD4þCD25þFo
panel) before and at 8 days after lymphocytic choriom
CD4þCD25þFoxP3þ regulatory T cells in the spleen (left panel) a
levels of Helios on CD4þCD25þFoxP3þ regulatory T cells in infect
LCMV-WE infection. (E) Serum levels of IL-10 in infected TTR-
Secretion of IL-10 by FoxP3þ-expressing cells among total splen
(left), and the proportion of IL-10 secreted by CD4þFoxP3þ regu
data of two to three independent experiments are shown; n ¼ 4Discussion
We found that expression of a viral protein by the liver
in the absence of inﬂammation can establish a state of
immunologic tolerance against the virus, leading to the
establishment of a persistent infection. This expression led
to the generation of regulatory T cells able to impede the
antiviral immune response, allowing acute LCMV strains to
persist with characteristics normally only observed during
chronic LCMV Clone 13 infection, such as T-cell exhaustion
and PD-1 up-regulation.18 Chronic infection with acute
LCMV-Arm or LCMV-WE strains has only been shown to
occur in either neonates19 or severely immunocompromised
animal models such as perforin-invalidated mice.20 How-
ever, TTR-NP mice are not immunodeﬁcient and mount
efﬁcient antiviral T- and B-cell responses against vesicular
stomatitis virus and clear infection (data not shown).
TTR-NP mice also develop an early type I interferon
response to LCMV similar to that of B6 mice. In vitro ex-
periments have shown that NP expression could inhibit the
type I interferon response.13 However, NP expression is
restricted to the hepatocytes in TTR-NP mice, and these cells
are not major producers of type I interferon during LCMV
infection.21
TTR-NP transgenic mice express NP speciﬁcally in he-
patocytes under the control of a modiﬁed TTR promoter and
do not express NP in the thymus.8 As evidenced by the
presence of NP-speciﬁc T cells after infection, extensive
central deletion of NP-reactive T lymphocytes does not
occur in these mice. This contrasts with a previous trans-
genic model tolerant to NP due to clonal deletion.22 The
active peripheral tolerance against NP in TTR-NP mice likely
stems from an expansion of or conversion to regulatory
CD4þ T cells.
FoxP3þ regulatory T cells are central to peripheral
tolerance both by their direct action on T cells but also by
keeping dendritic cells in an immature state that can then
efﬁciently induce peripheral tolerance.23 This regulatory
T cell-mediated active tolerance curbed the antiviral
response against NP-derived epitopes but also interfered
with CD4þ and CD8þ T-cell responses against GP-derived
epitopes. CD4þ regulatory T cells initially require TCR
stimulation to expand and initiate their suppressive effects,
but once this condition has been met, their ensuing sup-
pression can act in a non-antigen-speciﬁc way, in part
through IL-2 sequestration.24 Therefore, expansion of CD4þ
regulatory T cells at high levels after LCMV infection ofCD4D FoxP3D regulatory T cells expand after lymphocytic
eoprotein (TTR-NP) mice. (A) T-cell proliferation of adoptively
ctivating gene (RAG) and RAG-NP mice monitored by Ki-67
xP3þ regulatory T cells in spleen (left panel) and liver (right
eningitis virus (LCMV)-WE infection. (C) Proportions of
nd liver (right panel) at 55 days after infection. (D) Expression
ed TTR-NP (solid line) and B6mice (dotted line) at 55 days after
NP and B6 mice 8 to 147 days after LCMV-WE infection. (F)
ocytes from TTR-NPmice at 55 days after LCMV-WE infection
latory T cells in infected TTR-NP mice (right). (Representative
–8 per group.) *P < .05, **P < .01, ***P < .001.
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unspeciﬁc suppression of anti-LCMV responses, as seen by
the lower numbers of polyfunctional GP- and NP-speciﬁc
CD4þ and CD8þ T cells in chronically infected TTR-NP
mice.
Interestingly, there is an increased level of GP33–41-spe-
ciﬁc CD8þ T cells in the liver compared with the spleen at
55 days after LCMV infection. This suggests a greater
retention of these cells in the liver as opposed to the spleen
where GP33–41-speciﬁc CD8
þ T cell levels decline signiﬁ-
cantly compared with the levels found at day 8. This
increased retention likely stems from a combination of high
local viral burden and an inability of NP396–404 T cells to
exert an efﬁcient cytotoxic response, leading to a shift of
T-cell immunodominance in latter stages of infection in
these animals.
The expression levels of NP in TTR-NP mice also
contributed to the observed LCMV persistence because
hemizygous TTR-NP1/0 mice did not become chronically
infected after LCMV infection. Recently, Tay et al17 sug-
gested that low expression levels of a liver-antigen led to the
activation of CD8þ T cells with full effector functions
whereas high levels induced functional exhaustion. This
suggests that high NP expression in TTR-NP mice may have
led to exhaustion of NP-speciﬁc CD8þ T cells and could
explain why the CD4þ regulatory T-cell silencing/depletion
of infected TTR-NP, though leading to improved CD8þ T cell
responses and viral clearance, did not restore CD8þ T-cell
functionality up to B6 levels.
In addition to their classic roles of maintaining immu-
nologic tolerance to self and preventing autoimmunity,
CD4þ regulatory T cells can also inhibit immune responses
against pathogens. In HCV infection, the increased Treg
numbers correlate with higher viral burdens and increased
disease activity,25 and progression to persistent infection
correlates with an expansion of Gal-9-expressing regulatory
T cells.26 In nonhuman primates, subinfectious exposure to
HCV suppressed the T-cell responses against subsequent
HCV challenge through the generation of regulatory T
cells.27 Therefore, although the NP expression in transgenic
TTR-NP mice is artiﬁcial, expression of HCV viral proteins in
presence of low inﬂammation levels occurs and can lead to
the generation of regulatory T cells able to hinder the
antiviral immune response.
Regulatory T cells in TTR-NP mice express the Helios
transcription factor at higher levels than in B6 mice.Figure 8. (See previous page). Hemizygous transthyretin-n
phocytic choriomeningitis virus (LCMV) infection. (A) Express
NP1/0 mice as determined by ﬂow cytometry using ﬂuo
CD4þCD25þFoxP3þ regulatory T cells before infection in hemizy
cytometry. (C) Proportion of CD4þCD25þFoxP3þ regulatory T
TTR-NP, and B6 mice at 55 days after infection. (D) Proporti
NP1/0, TTR-NP, and B6 mice after stimulation with GP33–41 o
hemizygous TTR-NP1/0, TTR-NP, and B6 mice after LCMV-WE in
was performed using adoptive transfer of peptide pulsed (GP33
target cells in LCMV-infected and noninfected mice. Cells wer
titers 30 days after infection in hemizygous TTR-NP1/0, TTR-N
experiments are shown; n ¼ 4 per group.) *P < .05, **P < .01.Although initially believed to distinguish natural Tregs from
peripherally induced Tregs, the expression of the Helios
transcription factor has been recently reported in both
subsets28 and is now believed to reﬂect the context of
stimulation during FoxP3 induction.29 These observations
preclude using Helios as a marker of thymic Tregs, but its
expression is indicative of recent antigenic stimulation,29
suggesting that regulatory T cells of infected TTR-NP mice
might be more responsive to viral and/or endogenous NP
than those of B6 mice.
CD4þ FoxP3þ regulatory T cells actively secreted IL-10,
and its levels dramatically decreased after Treg depletion,
leading to viral clearance. Interestingly, IL-10 promoter poly-
morphisms can predict the initial response to IFN-a treatment
of HCV patients, with high producers of IL-10 responding
poorly to treatment.30 Moreover, early IL-10 predominant
responses havebeenassociatedwith an increased progression
to chronic HCV infection in injecting drug users.31
Infection with acute LCMV strains is not associated with
T-cell exhaustion.32 In TTR-NP mice, expression of the
T-cell exhaustion marker PD-1 on CD4þ and CD8þ T cells
correlated directly with LCMV titers after Treg depletion
and viral clearance (Pearson’s correlation, R2 ¼ 0.86, P ¼
.008, and R2 ¼ 0.88, P ¼ .0006, respectively), suggesting
that PD-1 expression by T cells is likely secondary to
chronic infection and high antigen levels. Thus, the PD-1
expression is triggered by TCR signaling; so long as LCMV
persists, PD-1 expression on LCMV-speciﬁc T cells will be
sustained.33 As a result, we speculate that Treg-mediated
tolerance against one viral antigen (NP) signiﬁcantly
impaired antiviral immune responses, leading to sustained
viral loads and high PD-1 expression levels on T cells. This
would explain why PD-1 expression is high on both GP and
NP-speciﬁc T cells after establishment of chronic LCMV
infection and decreases upon viral clearance after Treg
depletion. This is in agreement with recent ﬁndings by
Penaloza-MacMaster et al6 that showed signiﬁcantly
reduced viral titers upon CD4þ regulatory T-cell depletion
and PD-L1 blockade in mice infected with the chronic LCMV
strain Clone 13.
Anti-CD25 antibody-mediated silencing/depletion of
Tregs in infected TTR-NP mice led to improved T-cell
functionality and viral clearance. Anti-CD25 antibody-
mediated silencing/depletion of Tregs was chosen because
LCMV chronicity requires high NP expression, which
would be difﬁcult to achieve using an alternative methoducleoprotein (TTR-NP)1/0 (TTR-NP1/0) mice clear a lym-
ion levels of LCMV-NP in hepatocytes from hemizygous TTR-
rochrome-labeled NP-speciﬁc antibodies. (B) Number of
gous TTR-NP1/0, TTR-NP, and B6 mice as determined by ﬂow
cells after LCMV-WE infection in hemizygous TTR-NP1/0,
on of IFN-gþ TNF-aþ CD8þ T cells from hemizygous TTR-
r NP396–404 LCMV epitopes. (E) In vivo cytotoxicity assay in
fection at 30 days after infection. An in vivo cytotoxicity assay
–41, NP396–404, or negative control) CFSE-labeled splenocytes
e isolated and analyzed 4 hours after transfer. (F) LCMV-WE
P, and B6 mice. (Representative data of three independent
Figure 9. CD4D regulatory T cell (Treg) depletion/silencing leads to viral clearance. (A) Programmed death-1 (PD-1)
expression levels on T cells 8 and 28 days after anti-CD25-mediated Treg depletion performed 45 days after infection. (B)
Proportions of lymphocytic choriomeningitis virus (LCMV)-speciﬁc interferongþ (IFN-gþ) tumor necrosis factor-aþ (TNF-aþ)
CD8þ T cells from LCMV-WE-infected transthyretin-nucleoprotein (TTR-NP) mice at 10 and 28 days after Treg depletion. (C)
Interleukin-10 (IL-10) serum levels in LCMV-WE-infected TTR-NP mice after Treg depletion. (D) LCMV titers at 8 and 28 days
after Treg depletion in LCMV-infected TTR-NP mice. (Representative data of three independent experiments are shown; n ¼ 4
per group.) *P < .05.
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background.
In addition, the use of anti-CD25 has the beneﬁt of
potentially being translated more rapidly to clinicalapplication because daclizumab, an anti-CD25 humanized
antibody, is already approved for human use.34 Daclizumab
is used to treat acute-graft rejection by targeting CD25-
expressing effector T cells,34 but it has also been shown to
340 Lapierre et al Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 3effectively deplete CD4þ regulatory T cells in humans,
improving immune responses after tumor-antigen vaccina-
tion in patients with metastatic breast cancer.35
In conclusion, our results show that expression of a viral
protein by hepatocytes can induce a state of active periph-
eral tolerance, mediated by IL-10-expressing Tregs, sufﬁ-
cient to limit an antiviral T-cell response and lead to the
establishment of a chronic viral infection, which suggests
that interventions aimed at depleting or silencing Tregs
could be useful for the treatment of patients chronically
infected with hepatotropic viruses.
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Supplementary Figure 1. Flow cytometry gating strategies for class I and II tetramer staining. Isolated splenocytes
(2  106 cells) from infected mice were surface stained with anti-mouse antibodies for CD3ε, CD4, CD8, CD44, and appro-
priate class I (H2-Db NP396–404 or GP33–41) or class II (H2-IA
b NP309–328, GP66–77, GP31–45, or control H2-IA
b hCLIP)
ﬂuorochrome-labeled tetramers and with ﬂuorescent 7-AAD viability stain. Gating was performed according to these markers
to exclude doublets and dead cells and to analyze tetramer staining on either live CD3εþCD4CD8þ or CD3εþCD4þCD8
lymphocytes.
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